novartis india investor presentation

• Super Investors
•  Account
• Share Holding
• Balance Sheet
• Corp. Action

Novartis share price

NSE:  NOVARTIND BSE:  500672 SECTOR:  Trading   20k    38    4

Price Summary

₹  1035

₹  1011

₹  1224

₹  561.05

Ownership Stable

Valuation fair, efficiency poor, financials very stable, company essentials.

₹ 2533.77 Cr.

₹ 1977.83 Cr.

₹  295.19

₹ 555.94 Cr.

₹ 0 Cr.

₹  38.69

Add Your Ratio

Your Added Ratios

Index presence.

The company is present in 4 Indices.

S&P MIDSMLCAP

• Price Chart
• Volume Chart

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

Volume chart 1d 1w 1m 3m 6m 1yr 3yr 5yr, pe chart 1w 1m 3m 6m 1yr 3yr 5yr, pb chart 1w 1m 3m 6m 1yr 3yr 5yr, peer comparison,  group companies.

Track the companies of Group.

Sales Growth

Profit growth, debt/equity, price to cash flow, interest cover ratio, cfo/pat (5 yr. avg.).

Share Holding Pattern

Promoter pledging %,  strengths.

• The company has shown a good profit growth of 117.252103201553 % for the Past 3 years.
• Company is virtually debt free.
• Company has a healthy Interest coverage ratio of 66.9314285714286 .
• Company’s PEG ratio is 0.00921432956840993 .
• The company has an efficient Cash Conversion Cycle of -42.9235928261754 days.
• Company has a healthy liquidity position with current ratio of 2.93021695370163 .
• The company has a high promoter holding of 70.68 %.

 Limitations

• The company has shown a poor revenue growth of -4.74817736197044 % for the Past 3 years.
• Company has a poor ROE of 5.48144208459798 % over the past 3 years.
• Company has contingent liabilities of 419.25 Cr.
• Tax rate is low at 10.4177500433351 .

Quarterly Result (All Figures in Cr.)

Profit & loss (all figures in cr. adjusted eps in rs.), balance sheet (all figures are in crores.), cash flows (all figures are in crores.), corporate actions dividend bonus rights split, investors details promoter investors, annual reports.

• Annual Report 2022 1 Jul 2022
• Annual Report 2021 4 Aug 2021
• Annual Report 2020 11 Jul 2020
• Annual Report 2019 9 Jan 2020
• Annual Report 2018 9 Jan 2020
• Annual Report 2017 2 Apr 2021

Ratings & Research Reports

Company presentations.

Company News

Novartis stock price analysis and quick research report. is novartis an attractive stock to invest in.

Stock investing requires careful analysis of financial data to find out the company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement. This can be time-consuming and cumbersome. An easier way to find out about a company's performance is to look at its financial ratios, which can help to make sense of the overwhelming amount of information that can be found in a company's financial statements.

Here are the few indispensable tools that should be a part of every investor’s research process.

PE ratio : - Price to Earnings' ratio, which indicates for every rupee of earnings how much an investor is willing to pay for a share. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Novartis has a PE ratio of 17.3750662307285 which is high and comparatively overvalued .

Share Price : - The current share price of Novartis is Rs 672.25 . One can use valuation calculators of ticker to know if Novartis share price is undervalued or overvalued.

Return on Assets (ROA) : - Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Novartis has ROA of 5.08929406724998 % which is a bad sign for future performance. (higher values are always desirable)

Current ratio : - The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Novartis has a Current ratio of 2.93021695370163 .

Return on equity : - ROE measures the ability of a firm to generate profits from its shareholders investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Novartis has a ROE of 14.0662212000381 % .(higher is better)

Debt to equity ratio : - It is a good metric to check out the capital structure along with its performance. Novartis has a D/E ratio of 0 which means that the company has low proportion of debt in its capital.

Inventory turnover ratio : - Inventory Turnover ratio is an activity ratio and is a tool to evaluate the liquidity of a company's inventory. It measures how many times a company has sold and replaced its inventory during a certain period of time. Novartis has an Inventory turnover ratio of 8.22721173629126 which shows that the management is  inefficient in relation to its Inventory and working capital management.

Sales growth : - Novartis has reported revenue growth of - 5.28421737064545 % which is poor in relation to its growth and performance.

Operating Margin : - This will tell you about the operational efficiency of the company. The operating margin of Novartis for the current financial year is 17.1832919681048 %.

Dividend Yield : - It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Novartis is Rs 47.5  and the yield is 4.6027 %.

Brief about Novartis

Novartis india ltd. financials: check share price, balance sheet, annual report, quarterly results, shareholding, company profile and news for company analysis.

Novartis India Ltd. is a leading pharmaceutical company in India. It is a subsidiary of the global healthcare company Novartis AG. Novartis India has been operating in the country for several decades and has established itself as a trusted provider of high-quality medicines.

Novartis India Ltd. - Share Price

Stay updated with the latest share price of Novartis India Ltd. Our website provides real-time stock prices along with historical data. Our pre-built screening tools allow you to analyze the share price performance of Novartis India over different time periods.

Novartis India Ltd. - Balance Sheet

Access the balance sheet of Novartis India Ltd. on our website. Our premium features enable fair value calculation using tools such as DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis. These tools help long-term stock investors gain insights into the financial health of the company.

Novartis India Ltd. - Annual Report

Download the annual reports of Novartis India Ltd. from our website. The annual reports provide a comprehensive overview of the company's performance, financials, and strategic initiatives. They are valuable resources for investors to assess the company's long-term prospects.

Novartis India Ltd. - Dividend

Track the dividend history of Novartis India Ltd. on our website. Dividends are an important consideration for many investors looking for stable income from their investments. Novartis India regularly evaluates and announces dividends to reward its shareholders.

Novartis India Ltd. - Quarterly Results

Stay informed about the quarterly results of Novartis India Ltd. Our website provides access to the latest financial reports and insights from earnings calls. These reports help investors track the company's performance and make informed investment decisions.

Novartis India Ltd. - Stock Price

Analyze the stock price movement of Novartis India Ltd. on our website. Our pre-built screening tools and price charts allow investors to track the stock's historical performance and identify potential investment opportunities.

Novartis India Ltd. - Price Chart

Visualize the price chart of Novartis India Ltd. on our website. Price charts provide a graphical representation of the stock's price movement over time, helping investors spot trends, patterns, and potential support and resistance levels.

Novartis India Ltd. - News

Access the latest news updates about Novartis India Ltd. Our website provides a curated feed of news articles and press releases related to the company. Stay informed about the latest developments that may impact your investment decisions.

Novartis India Ltd. - Concall Transcripts

Download the concall transcripts of Novartis India Ltd. from our website. Concall transcripts are valuable resources that provide insights into the company's performance, management commentary, and future outlook as discussed during the earnings calls.

Novartis India Ltd. - Investor Presentations

Find investor presentations of Novartis India Ltd. on our website. Investor presentations offer a comprehensive overview of the company's strategy, financials, and operational highlights. These presentations are useful for investors to understand the company's business and investment potential.

Novartis India Ltd. - Promoters

Learn about the promoters of Novartis India Ltd. Promoters play a crucial role in the company's management and decision-making process. Our website provides information about the promoters and their contribution to the company's growth.

Novartis India Ltd. - Shareholders

Explore information about the shareholders of Novartis India Ltd. Shareholders play a significant role in the company's ownership and governance. Our website provides insights into the major shareholders of Novartis India and their stake in the company.

By providing comprehensive stock analysis tools, access to key financial reports, and curated news updates, our website aims to empower long-term stock investors in making informed decisions regarding Novartis India Ltd. Stay updated with the latest information and leverage our premium features for fair value calculations and in-depth analysis.

Ratio Delete Confirmation

Novartis India Ltd

Performance

Hasn't fared well - amongst the low performers

Seems to be overvalued vs the market average

Financials growth has been moderate for a few years

Profitability

Showing good signs of profitability & efficiency

Entry point

The stock is overpriced but is not in the overbought zone

No red flag found

Go Pro! to unlock score, rank

and other metrics

How to use scorecard? Learn more

Financial Statements

Balance Sheet

What is an income statement?

The income statement indicates a company's financial performance measured over a reporting period. Performance is assessed by summarising how the business incurs its revenues, expenses and net profit or loss incurred over the period. It's also called the P&L statement

Income Statement

Lower than industry revenue growth a higher-than-industry revenue growth represents increased potential for the company to increase their market share.

Over the last 5 years, revenue has grown at a yearly rate of -9.9%, vs industry avg of 8.36%

Decreasing Market Share Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share decreased from 0.36% to 0.13%

Lower than Industry Net Income Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 5.69%, vs industry avg of 9.82%

EPS and DPS in ₹. Other numbers except Payout Ratio in ₹ cr

Company Updates

Annual report

Novartis India Ltd

Novartis India Ltd is primarily engaged in the Business of Wholesale of pharmaceuticals and medical goods. [1] It imports various medicines to India from different sources across the globe. [2]

Therapeutic Segments The company's pharmaceutical business is focused on bone & pain, calcium portfolio, gynecology and neurosciences. Its generics business is focused on gynecology, anti-TB and anti-infectives. [1]

• Market Cap ₹ 2,534 Cr.
• Current Price ₹ 1,026
• High / Low ₹ 1,224 / 561
• Stock P/E 26.5
• Book Value ₹ 284
• Dividend Yield 0.97 %
• ROCE 15.1 %
• Face Value ₹ 5.00
• Sales & Margin
• EV / EBITDA
• Price to Book
• Market Cap / Sales
• Company has reduced debt.
• Company is almost debt free.
• Stock is trading at 3.61 times its book value
• The company has delivered a poor sales growth of -7.65% over past five years.
• Company has a low return on equity of 7.56% over last 3 years.
• Earnings include an other income of Rs.67.6 Cr.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Trading Industry: Trading

Quarterly Results

Figures in Rs. Crores

Profit & Loss

Balance sheet, shareholding pattern.

Numbers in percentages

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards. Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes. Click on the line-items to see the names of individual entities.

Announcements

• Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 20 Apr
• Compliances - Reg. 40(10) - PCS Certificate For Transfer / Transmission / Transposition 15 Apr
• Compliances - Compliance Certificate For The Period Ended March 31, 2024 10 Apr - Certificate under Regulation 7(3) of SEBI (LODR) Regulations, 2015
• Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 8 Apr
• Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer 1 Apr

Annual reports

• Financial Year 2023 from bse
• Financial Year 2022 from bse
• Financial Year 2021 from bse
• Financial Year 2020 from bse
• Financial Year 2019 from bse
• Financial Year 2018 from bse
• Financial Year 2017 from bse
• Financial Year 2016 from bse
• Financial Year 2015 from bse
• Financial Year 2014 from bse
• Financial Year 2013 from bse
• Financial Year 2012 from bse
• Financial Year 2011 from bse
• Financial Year 2010 from bse

• NOVARTIS INDIA LTD.
• SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY
• INDUSTRY : PHARMACEUTICALS

Novartis India Ltd. BSE: 500672

Strong Performer, Getting Expensive

Novartis India Ltd. Live Share Price Today, Share Analysis and Chart

1026.20 1.75 ( 0.17 %)

82.91% Gain from 52W Low

7,225 BSE Volume

BSE 24 Apr, 2024 3:31 PM (IST)

• Share on Facebook
• Share on LinkedIn
• Share via Whatsapp

Novartis India Ltd. Live Price Chart

Earnings conference calls, investor presentations and annual reports, annual reports, novartis india ltd. faq, how is the novartis india ltd. today, the novartis india ltd. today is trading in the green, up by 0.17% at 1026.20., how has novartis india ltd. performed historically, the novartis india ltd. is currently trading up 0.17% on an intraday basis. in the past week the stock fell -0.79%. the stock has been up 16.28% in the past quarter and rose 77.64% in the past year. you can view this in the overview section..

Novartis India Ltd

Price Chart

Performance

Hasn't fared well - amongst the low performers

Seems to be overvalued vs the market average

Financials growth has been moderate for a few years

Profitability

Showing good signs of profitability & efficiency

Entry point

The stock is overpriced but is not in the overbought zone

No red flag found

Go Pro! to unlock score, rank

and other metrics

How to use scorecard? Learn more

Key Metrics

Forecast & ratings, price upside, earnings growth, rev. growth, company profile.

Novartis India Limited manufactures drugs, medicines and allied products. The Company is engaged in the wholesale of pharmaceuticals and medical goods.

Sun Pharmaceutical Industries Ltd

Dr reddy's laboratories ltd, zydus lifesciences ltd, mankind pharma ltd, get more out of tickertape, go pro.

Customise key metrics, see detailed forecasts, download stock data and more

Already a Pro member? Login

Price Forecast

Revenue forecast, earnings per share forecast.

Balance Sheet

Income Statement

Lower than industry revenue growth.

Over the last 5 years, revenue has grown at a yearly rate of -9.9%, vs industry avg of 8.36%

Decreasing Market Share

Over the last 5 years, market share decreased from 0.36% to 0.13%

Lower than Industry Net Income

Over the last 5 years, net income has grown at a yearly rate of 5.69%, vs industry avg of 9.82%

EPS and DPS in ₹. Other numbers except Payout Ratio in ₹ cr

Company Updates

Annual report

Peers & Comparison

Price comparison, shareholdings, promoter holdings trend, total promoter holding.

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Total retail holding.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding

In last 3 months, foreign institutional holding of the company has almost stayed constant

Shareholding Pattern

Shareholding history, insider trades & bulk deals.

Looks like this stock is not in any smallcase yet.

Dividend Trend

No dividend cuts.

NOVARTIND has increased or maintained dividend levels over the last 5 years

Dividend Yield

Current dividend yield is 4.64%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹46.37 every year

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash dividend.

Ex Date Ex Date Jul 20, 2023

Dividend/Share

Ex Date Ex Date

Jul 20, 2023

Ex Date Ex Date Jul 20, 2022

Jul 20, 2022

Ex Date Ex Date Aug 17, 2021

Aug 17, 2021

Ex Date Ex Date Jul 29, 2020

Jul 29, 2020

News & Opinions

Rmi scanner generates new ‘buy’ signal in these 4 stocks; do you own any.

2 months ago • Moneycontrol

Novartis India Share Price: हिस्सा बिक्री की खबर से Stock में 11% की तेजी है, DRL का रोल क्या? |News

2 months ago • CNBC Awaaz.

Dr. Reddy’s Hits Life High On Reports Of Acquiring Novartis India

2 months ago • Bloomberg Quint

Novartis Starts ‘Strategic Review’ Of India Listed Business Amid Reports Of Sale Talks

Novartis india standalone net profit rises 161.40% in the september 2022 quarter.

1 year ago • Business Standard

Novartis India standalone net profit rises 734.08% in the June 2022 quarter

Novartis india standalone march 2022 net sales at rs 98.32 crore, down 0.98% y-o-y.

1 year ago • Moneycontrol